| 1. |
日本人の再発又は難治性のマントル細胞リンパ腫に対するベネトクラクスとイブルチニブの併用療法の長期フォローアップ成績 （口頭発表，一般） 2025/03/07
|
| 2. |
Analysis of Pola+R-CHP chemotherapy for large B-cell lymphoma in our institution （口頭発表，一般） 2024/10
|
| 3. |
Bone marrow collision tumor of plasma cell neoplasm and signet ring cell carcinoma （ポスター，一般） 2024/10
|
| 4. |
Immune thrombocytopenia following vaccination against SARS-CoV-2 coronavirus which underwent autopsy （ポスター，一般） 2024/10
|
| 5. |
A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage. （ポスター，一般） 2023/12
|
| 6. |
Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes. （口頭発表，一般） 2023/12
|
| 7. |
Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma. （ポスター，一般） 2023/12
|
| 8. |
The Seven-Color FISH Analysis Can Detect the Acquisition Pattern of Complex Chromosomal Abnormalities Related to Poor Response and Prognosis in Patients with Multiple Myeloma. （ポスター，一般） 2023/12
|
| 9. |
JAK2V617F遺伝子変異陽性の本体性血小板血症から移行したt(8;21)陽性急性骨髄性白血病 （口頭発表，一般） 2023/10
|
| 10. |
Von Willebrand病type再判断のための医療連携の必要性とその手順 （口頭発表，一般） 2023/10
|
| 11. |
低形成骨髄を呈した本態性血小板血症 （口頭発表，一般） 2023/10
|
| 12. |
３系統の免疫性血球減少を呈した骨髄病変を有するIgG4関連疾患 （口頭発表，一般） 2023/10
|
| 13. |
A phase 3 trial of bendamustine/rituximab for relapsed or refractory diffuse large b-cell lymphoma （口頭発表，一般） 2021/09
|
| 14. |
Blastic plasmacytoid dendritic cell neoplasm lacking CD4 expression （ポスター，一般） 2021/09
|
| 15. |
Co-expression of chromosomal abnormalities predict poor responsibility for EPD treatment （ポスター，一般） 2021/09
|
| 16. |
Long term prognosis of patient with chronic DIC who has ITP （ポスター，一般） 2021/09
|
| 17. |
Two cases of lymphoplasmacytic lymphoma presenting lymphomatous infiltration of the kidneys （ポスター，一般） 2021/09
|
| 18. |
免疫性血小板減少症の経過中に顕在化しTKI 治療により血小板の増加が得られた慢性骨髄性白血病 （口頭発表，一般） 2021/03
|
| 19. |
Carfilzomib regimen in patients with multiple myeloma intolerable or relapsed to VRD induction （口頭発表，一般） 2020/10
|
| 20. |
Efficacy and safety of bendamustine in elderly patients with R/R low-grade B-cell lymphoma and MCL （口頭発表，一般） 2020/10
|
| 21. |
Final analysis of a phase 2 study of ixazomib plus LenDex in Japanese RRMM patients （口頭発表，一般） 2020/10
|
| 22. |
KEYNOTE-204: phase 3 study of pembrolizumab vs brentuximab vedotin in R/R classical Hodgkin lymphoma （口頭発表，一般） 2020/10
|
| 23. |
Phase 2 study of E7777 on relapsed or refractory, peripheral and cutaneous T-cell lymphoma in Japan （口頭発表，一般） 2020/10
|
| 24. |
Phase II study of tirabrutinib in Japanese patients with Waldenstrom's macroglobulinemia （口頭発表，一般） 2020/10
|
| 25. |
Polatuzumab vedotin with bendamustine and rituximab in r/r DLBCL (P-DRIVE): A phase 2 study in Japan （口頭発表，一般） 2020/10
|
| 26. |
Transformed follicular lymphoma in relation with rituximab maintenance and chromosome 8 aberrations （口頭発表，一般） 2020/10
|
|
5件表示
|
|
全件表示(26件)
|